Prostate Cancer Institute, Cancer Care Centre, St George Hospital Clinical School of Medicine, University of New South Wales, Kogarah, NSW 2217, Australia.
Cancers (Basel). 2010 Jun 4;2(2):1125-54. doi: 10.3390/cancers2021125.
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnosis will benefit an individual patient, but also as a result of the imprecise and invasive nature of establishing a diagnosis by biopsy. Despite its low sensitivity and specificity for identifying patients harbouring prostate cancer, serum prostate specific antigen (PSA) has become established as the most reliable and widely-used diagnostic marker for this condition. In its wake, many other markers have been described and evaluated. This review focuses on the supporting evidence for the most prominent of these for detection and also for predicting outcome in prostate cancer.
前列腺癌的早期检测存在问题，不仅因为诊断是否对个体患者有益存在不确定性，还因为通过活检确定诊断的不精确和侵入性。尽管血清前列腺特异性抗原 (PSA) 用于识别患有前列腺癌的患者的敏感性和特异性较低，但它已成为该疾病最可靠和广泛使用的诊断标志物。在此之后，已经描述和评估了许多其他标志物。本综述重点介绍了这些标志物中最突出的用于检测和预测前列腺癌结局的证据。
